Fig. 2From: Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United StatesPFS for nontransplanted NDMM patients treated with VRd as first LOTPFS progression-free survival, NDMM newly diagnosed multiple myeloma, VRd bortezomib with lenalidomide and dexamethasone, LOT line of therapyBack to article page